Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Optimer gains on further take out rumors

Shares of Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) jumped $1.85 (14%) to $14.66 on Monday after media reports surfaced that at

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE